FindTrial
Sign In

A Study to compare the effects of topical tofacitinib 2% ointment alone with the effects of combination of topical tofacitinib 2% ointment and excimer laser in the treatment of stable vitiligo

A COMPARATIVE STUDY ON THE THERAPEUTIC EFFICACY OF TOPICAL TOFACITINIB 2 PERCENT OINTMENT WITH EXCIMER LASER 308nm VERSUS TOPICAL TOFACITINIB 2 PERCENT OINTMENT MONOTHERAPY IN STABLE - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/106939
Enrollment
52
Registered
2026-03-27
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: tofacitinib 0.2% ointment plus excimer (308nm) laser: tofacitinib 0.2% ointment Frequency- Twice Daily Route - Topical application over the lesions with excimer 308nm laser twice we

Sponsors

ERAS LUCKNOW MEDICAL COLLEGE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Stable vitiligo patients aged between 18 and 80, of either gender with clinical diagnosis of stable vitiligo Involving less than 5% of body surface area, attending the Dermatology OPD at ELMC&H.

Exclusion criteria

Exclusion criteria: Vitiligo patients who took treatment in last 3 months. Patient having hypersensitivity to topical tofacitinib (2%) ointment. History of photosensitivity disorders or contraindications to phototherapy. History of intolerance to Excimer (308nm) light. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
To compare the efficacy of topical tofacitinib (2%) ointment combined with excimer laser (308nm) therapy, with topical tofacitinib (2%) ointment monotherapy, in achieving repigmentation in patients with stable vitiligo.Timepoint: 0,4,8,12,16 weeks—

Secondary

MeasureTime frame
To identify any adverse effects with use of topical tofacitinib (2%) ointment, excimer laser (308nm) and their combination in stable vitiligo.Timepoint: 0,4,8,12,16 weeks.—

Countries

India

Contacts

Public ContactSHREYA PODDAR

Eras Lucknow Medical College And Hospital

Savitagarg3@gmail.com7839316909

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026